• HERACLES clinical trial of SOF-SKN begins
• External interest continues with scope expansions of Sofra collaborations
• Sofra scientific presentations at international events

Noxopharm Limited (ASX:NOX) has provided its Quarterly Activities Report for the period ending 30 June 2025. Key highlights include the start of the HERACLES clinical trial for the company's Sofra drug candidate SOF-SKN and the expansion of existing Sofra collaborations with external companies. During the quarter, Noxopharm expanded the scope of its collaborations with three companies following the signing of Material Transfer Agreements (MTAs) several months previously, demonstrating ongoing interest in the Sofra technology platform. The company also announced positive data generated by BioRay Pharmaceutical, a pioneer in China's biopharmaceutical industry. Additionally, Noxopharm executives and team members continued to promote the Sofra platform at various national and international conferences and events. In the June quarter, the company achieved the milestone of taking an asset from the Sofra platform into a human clinical trial with the HERACLES trial of SOF-SKN. This represents a sustained effort from the company to leverage the Sofra platform and demonstrate its potential. The company sees the development of SOF-SKN as just the first step in leveraging the Sofra platform to tackle much larger markets, such as autoimmune diseases that affect millions of people worldwide.

The company continues to be vigilant with its cash resources and is exploring a range of options in relation to securing additional capital. It is looking at its strategic plan and exploring the likelihood of short-term catalysts which may impact the timing and range of options to secure follow-on funding. The company has been in active discussion with various parties in relation to securing additional funding in the short term in order to ensure the extension of its financial runway.